anti vegf antibody (Genentech)
86
Structured Review
Genentech
anti vegf antibody
Anti Vegf Antibody, supplied by Genentech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti vegf antibody/product/Genentech
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
Anti Vegf Antibody, supplied by Genentech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti vegf antibody/product/Genentech
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
anti vegf antibody - by Bioz Stars,
2021-03
86/100 stars
Images
1) Product Images from "Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice"
Article Title: Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice
Journal: PLoS ONE
doi: 10.1371/journal.pone.0134308
Figure Legend Snippet: Ocular and systemic consequences of intravitreally injected anti-VEGF antibody. (A) Effects of intravitreally injected anti-VEGF antibody (1 μg/eye) on retinal neovascularization in OIR mice ( n = 6). Neovascular tufts were highlighted with yellow pseudocolor on representative images of isolectin B4-stained retina. The area of neovascular tufts was normalized to total retinal area; then, the effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). Scale bar, 200 μm. (B) Retinal VEGF concentrations at P17 with intravitreal injection of PBS or anti-VEGF antibody ( n = 3). The level of VEGF was normalized to total amounts of proteins in the retina. (C) Serum concentrations of anti-VEGF antibody after intravitreal injection at P14, P17, and P21 ( n = 3–6). (D) Serum VEGF concentrations after intravitreal injection of anti-VEGF antibody at P17, P21, and P28 ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. NS , not significant; **, P
Techniques Used: Injection, Mouse Assay, Staining
Figure Legend Snippet: Long-term effects of intravitreally injected anti-VEGF antibody on BAT. (A) Quantitative analyses of the number of large lipid droplets ( > 50 μm 2 ) per field at x400 magnification ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (B) Quantitative analyses of vascularity of interscapular BAT demonstrated by isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (C) The changes in body weight from P14 to P56. Anti-VEGF, anti-VEGF antibody. NS , not significant (two-tailed, unpaired T-test).
Techniques Used: Injection, Staining, Two Tailed Test
Figure Legend Snippet: Ocular and systemic consequences of intravitreally injected anti-VEGF antibody. (A) Effects of intravitreally injected anti-VEGF antibody (1 μg/eye) on retinal neovascularization in OIR mice ( n = 6). Neovascular tufts were highlighted with yellow pseudocolor on representative images of isolectin B4-stained retina. The area of neovascular tufts was normalized to total retinal area; then, the effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). Scale bar, 200 μm. (B) Retinal VEGF concentrations at P17 with intravitreal injection of PBS or anti-VEGF antibody ( n = 3). The level of VEGF was normalized to total amounts of proteins in the retina. (C) Serum concentrations of anti-VEGF antibody after intravitreal injection at P14, P17, and P21 ( n = 3–6). (D) Serum VEGF concentrations after intravitreal injection of anti-VEGF antibody at P17, P21, and P28 ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. NS , not significant; **, P
Techniques Used: Injection, Mouse Assay, Staining
Figure Legend Snippet: Effects of intravitreally injected anti-VEGF antibody on BAT of neonatal mice. (A) Concentrations of VEGF in interscapular BAT at P21 and P28. The level of VEGF was normalized to total amounts of proteins in BAT ( n = 3–6). (B) Representative images of H E staining of interscapular BAT after intravitreal injection of PBS or anti-VEGF antibody show enlarged lipid droplets. Scale bar, 20 μm. (C) Quantitative analyses of vascularity of interscapular BAT based on isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). (D) Relative expression of Ucp1 and Ppargc1a in interscapular BAT ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. *, P
Techniques Used: Injection, Mouse Assay, Staining, Expressing
2) Product Images from "Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice"
Article Title: Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice
Journal: PLoS ONE
doi: 10.1371/journal.pone.0134308
Figure Legend Snippet: Long-term effects of intravitreally injected anti-VEGF antibody on BAT. (A) Quantitative analyses of the number of large lipid droplets ( > 50 μm 2 ) per field at x400 magnification ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (B) Quantitative analyses of vascularity of interscapular BAT demonstrated by isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (C) The changes in body weight from P14 to P56. Anti-VEGF, anti-VEGF antibody. NS , not significant (two-tailed, unpaired T-test).
Techniques Used: Injection, Staining, Two Tailed Test
Figure Legend Snippet: Ocular and systemic consequences of intravitreally injected anti-VEGF antibody. (A) Effects of intravitreally injected anti-VEGF antibody (1 μg/eye) on retinal neovascularization in OIR mice ( n = 6). Neovascular tufts were highlighted with yellow pseudocolor on representative images of isolectin B4-stained retina. The area of neovascular tufts was normalized to total retinal area; then, the effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). Scale bar, 200 μm. (B) Retinal VEGF concentrations at P17 with intravitreal injection of PBS or anti-VEGF antibody ( n = 3). The level of VEGF was normalized to total amounts of proteins in the retina. (C) Serum concentrations of anti-VEGF antibody after intravitreal injection at P14, P17, and P21 ( n = 3–6). (D) Serum VEGF concentrations after intravitreal injection of anti-VEGF antibody at P17, P21, and P28 ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. NS , not significant; **, P
Techniques Used: Injection, Mouse Assay, Staining
3) Product Images from "Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice"
Article Title: Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice
Journal: PLoS ONE
doi: 10.1371/journal.pone.0134308
Figure Legend Snippet: Long-term effects of intravitreally injected anti-VEGF antibody on BAT. (A) Quantitative analyses of the number of large lipid droplets ( > 50 μm 2 ) per field at x400 magnification ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (B) Quantitative analyses of vascularity of interscapular BAT demonstrated by isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (C) The changes in body weight from P14 to P56. Anti-VEGF, anti-VEGF antibody. NS , not significant (two-tailed, unpaired T-test).
Techniques Used: Injection, Staining, Two Tailed Test
Figure Legend Snippet: Ocular and systemic consequences of intravitreally injected anti-VEGF antibody. (A) Effects of intravitreally injected anti-VEGF antibody (1 μg/eye) on retinal neovascularization in OIR mice ( n = 6). Neovascular tufts were highlighted with yellow pseudocolor on representative images of isolectin B4-stained retina. The area of neovascular tufts was normalized to total retinal area; then, the effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). Scale bar, 200 μm. (B) Retinal VEGF concentrations at P17 with intravitreal injection of PBS or anti-VEGF antibody ( n = 3). The level of VEGF was normalized to total amounts of proteins in the retina. (C) Serum concentrations of anti-VEGF antibody after intravitreal injection at P14, P17, and P21 ( n = 3–6). (D) Serum VEGF concentrations after intravitreal injection of anti-VEGF antibody at P17, P21, and P28 ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. NS , not significant; **, P
Techniques Used: Injection, Mouse Assay, Staining
Figure Legend Snippet: Effects of intravitreally injected anti-VEGF antibody on BAT of neonatal mice. (A) Concentrations of VEGF in interscapular BAT at P21 and P28. The level of VEGF was normalized to total amounts of proteins in BAT ( n = 3–6). (B) Representative images of H E staining of interscapular BAT after intravitreal injection of PBS or anti-VEGF antibody show enlarged lipid droplets. Scale bar, 20 μm. (C) Quantitative analyses of vascularity of interscapular BAT based on isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). (D) Relative expression of Ucp1 and Ppargc1a in interscapular BAT ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. *, P
Techniques Used: Injection, Mouse Assay, Staining, Expressing
4) Product Images from "Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice"
Article Title: Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice
Journal: PLoS ONE
doi: 10.1371/journal.pone.0134308
Figure Legend Snippet: Long-term effects of intravitreally injected anti-VEGF antibody on BAT. (A) Quantitative analyses of the number of large lipid droplets ( > 50 μm 2 ) per field at x400 magnification ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (B) Quantitative analyses of vascularity of interscapular BAT demonstrated by isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (C) The changes in body weight from P14 to P56. Anti-VEGF, anti-VEGF antibody. NS , not significant (two-tailed, unpaired T-test).
Techniques Used: Injection, Staining, Two Tailed Test
Figure Legend Snippet: Ocular and systemic consequences of intravitreally injected anti-VEGF antibody. (A) Effects of intravitreally injected anti-VEGF antibody (1 μg/eye) on retinal neovascularization in OIR mice ( n = 6). Neovascular tufts were highlighted with yellow pseudocolor on representative images of isolectin B4-stained retina. The area of neovascular tufts was normalized to total retinal area; then, the effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). Scale bar, 200 μm. (B) Retinal VEGF concentrations at P17 with intravitreal injection of PBS or anti-VEGF antibody ( n = 3). The level of VEGF was normalized to total amounts of proteins in the retina. (C) Serum concentrations of anti-VEGF antibody after intravitreal injection at P14, P17, and P21 ( n = 3–6). (D) Serum VEGF concentrations after intravitreal injection of anti-VEGF antibody at P17, P21, and P28 ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. NS , not significant; **, P
Techniques Used: Injection, Mouse Assay, Staining
Figure Legend Snippet: Effects of intravitreally injected anti-VEGF antibody on BAT of neonatal mice. (A) Concentrations of VEGF in interscapular BAT at P21 and P28. The level of VEGF was normalized to total amounts of proteins in BAT ( n = 3–6). (B) Representative images of H E staining of interscapular BAT after intravitreal injection of PBS or anti-VEGF antibody show enlarged lipid droplets. Scale bar, 20 μm. (C) Quantitative analyses of vascularity of interscapular BAT based on isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). (D) Relative expression of Ucp1 and Ppargc1a in interscapular BAT ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. *, P
Techniques Used: Injection, Mouse Assay, Staining, Expressing
Figure Legend Snippet: Long-term effects of intravitreally injected anti-VEGF antibody on BAT. (A) Quantitative analyses of the number of large lipid droplets ( > 50 μm 2 ) per field at x400 magnification ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (B) Quantitative analyses of vascularity of interscapular BAT demonstrated by isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (C) The changes in body weight from P14 to P56. Anti-VEGF, anti-VEGF antibody. NS , not significant (two-tailed, unpaired T-test).
Techniques Used: Injection, Staining, Two Tailed Test
Figure Legend Snippet: Ocular and systemic consequences of intravitreally injected anti-VEGF antibody. (A) Effects of intravitreally injected anti-VEGF antibody (1 μg/eye) on retinal neovascularization in OIR mice ( n = 6). Neovascular tufts were highlighted with yellow pseudocolor on representative images of isolectin B4-stained retina. The area of neovascular tufts was normalized to total retinal area; then, the effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). Scale bar, 200 μm. (B) Retinal VEGF concentrations at P17 with intravitreal injection of PBS or anti-VEGF antibody ( n = 3). The level of VEGF was normalized to total amounts of proteins in the retina. (C) Serum concentrations of anti-VEGF antibody after intravitreal injection at P14, P17, and P21 ( n = 3–6). (D) Serum VEGF concentrations after intravitreal injection of anti-VEGF antibody at P17, P21, and P28 ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. NS , not significant; **, P
Techniques Used: Injection, Mouse Assay, Staining
Figure Legend Snippet: Effects of intravitreally injected anti-VEGF antibody on BAT of neonatal mice. (A) Concentrations of VEGF in interscapular BAT at P21 and P28. The level of VEGF was normalized to total amounts of proteins in BAT ( n = 3–6). (B) Representative images of H E staining of interscapular BAT after intravitreal injection of PBS or anti-VEGF antibody show enlarged lipid droplets. Scale bar, 20 μm. (C) Quantitative analyses of vascularity of interscapular BAT based on isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). (D) Relative expression of Ucp1 and Ppargc1a in interscapular BAT ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. *, P
Techniques Used: Injection, Mouse Assay, Staining, Expressing
5) Product Images from "Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy"
Article Title: Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy
Journal: Oncotarget
doi: 10.18632/oncotarget.20410
Figure Legend Snippet: AC708 reduces tumor burden in setting of adaptive resistance to anti-VEGF therapy Bioluminescent signal differences between B20 resistant mice with and without the addition of AC708 are shown. Automatic exposure time was used A. . Tumor weight, tumor nodules, and volume of ascites B. - D. are shown in IG10 murine ovarian cancer model of adaptive resistance treated with AC708, B20, or the combination, after resistance was determined by bioluminescent imaging. E. demonstrates bioluminescence imaging differences in those mice sensitive versus resistant to treatment with bevacizumab and paclitaxel in OVCAR432 HGSC model. Automatic exposure was time was used. Tumor weight of the OVCAR432 model shown in groups resistant to bevacizumab, plus paclitaxel, with and without AC708 F. . G. Quantification of macrophages from IG10 model treated with AC708, B20, or the combination in the setting of adaptive resistance. Macrophage content was determined by the percentage of CD11b + /F4/80 + cells out of CD45 + cells, using flow cytometry. The same groups were also stained for F4/80 via immunohistochemistry to quantify macrophages H. . **** denotes p≤0.0001.
Techniques Used: Mouse Assay, Imaging, Flow Cytometry, Cytometry, Staining, Immunohistochemistry
6) Product Images from "Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice"
Article Title: Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice
Journal: PLoS ONE
doi: 10.1371/journal.pone.0134308
Figure Legend Snippet: Long-term effects of intravitreally injected anti-VEGF antibody on BAT. (A) Quantitative analyses of the number of large lipid droplets ( > 50 μm 2 ) per field at x400 magnification ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (B) Quantitative analyses of vascularity of interscapular BAT demonstrated by isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (C) The changes in body weight from P14 to P56. Anti-VEGF, anti-VEGF antibody. NS , not significant (two-tailed, unpaired T-test).
Techniques Used: Injection, Staining, Two Tailed Test
Figure Legend Snippet: Ocular and systemic consequences of intravitreally injected anti-VEGF antibody. (A) Effects of intravitreally injected anti-VEGF antibody (1 μg/eye) on retinal neovascularization in OIR mice ( n = 6). Neovascular tufts were highlighted with yellow pseudocolor on representative images of isolectin B4-stained retina. The area of neovascular tufts was normalized to total retinal area; then, the effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). Scale bar, 200 μm. (B) Retinal VEGF concentrations at P17 with intravitreal injection of PBS or anti-VEGF antibody ( n = 3). The level of VEGF was normalized to total amounts of proteins in the retina. (C) Serum concentrations of anti-VEGF antibody after intravitreal injection at P14, P17, and P21 ( n = 3–6). (D) Serum VEGF concentrations after intravitreal injection of anti-VEGF antibody at P17, P21, and P28 ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. NS , not significant; **, P
Techniques Used: Injection, Mouse Assay, Staining
Figure Legend Snippet: Effects of intravitreally injected anti-VEGF antibody on BAT of neonatal mice. (A) Concentrations of VEGF in interscapular BAT at P21 and P28. The level of VEGF was normalized to total amounts of proteins in BAT ( n = 3–6). (B) Representative images of H E staining of interscapular BAT after intravitreal injection of PBS or anti-VEGF antibody show enlarged lipid droplets. Scale bar, 20 μm. (C) Quantitative analyses of vascularity of interscapular BAT based on isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). (D) Relative expression of Ucp1 and Ppargc1a in interscapular BAT ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. *, P
Techniques Used: Injection, Mouse Assay, Staining, Expressing
7) Product Images from "Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice"
Article Title: Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice
Journal: PLoS ONE
doi: 10.1371/journal.pone.0134308
Figure Legend Snippet: Ocular and systemic consequences of intravitreally injected anti-VEGF antibody. (A) Effects of intravitreally injected anti-VEGF antibody (1 μg/eye) on retinal neovascularization in OIR mice ( n = 6). Neovascular tufts were highlighted with yellow pseudocolor on representative images of isolectin B4-stained retina. The area of neovascular tufts was normalized to total retinal area; then, the effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). Scale bar, 200 μm. (B) Retinal VEGF concentrations at P17 with intravitreal injection of PBS or anti-VEGF antibody ( n = 3). The level of VEGF was normalized to total amounts of proteins in the retina. (C) Serum concentrations of anti-VEGF antibody after intravitreal injection at P14, P17, and P21 ( n = 3–6). (D) Serum VEGF concentrations after intravitreal injection of anti-VEGF antibody at P17, P21, and P28 ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. NS , not significant; **, P
Techniques Used: Injection, Mouse Assay, Staining
Figure Legend Snippet: Long-term effects of intravitreally injected anti-VEGF antibody on BAT. (A) Quantitative analyses of the number of large lipid droplets ( > 50 μm 2 ) per field at x400 magnification ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (B) Quantitative analyses of vascularity of interscapular BAT demonstrated by isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (C) The changes in body weight from P14 to P56. Anti-VEGF, anti-VEGF antibody. NS , not significant (two-tailed, unpaired T-test).
Techniques Used: Injection, Staining, Two Tailed Test
Figure Legend Snippet: Ocular and systemic consequences of intravitreally injected anti-VEGF antibody. (A) Effects of intravitreally injected anti-VEGF antibody (1 μg/eye) on retinal neovascularization in OIR mice ( n = 6). Neovascular tufts were highlighted with yellow pseudocolor on representative images of isolectin B4-stained retina. The area of neovascular tufts was normalized to total retinal area; then, the effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). Scale bar, 200 μm. (B) Retinal VEGF concentrations at P17 with intravitreal injection of PBS or anti-VEGF antibody ( n = 3). The level of VEGF was normalized to total amounts of proteins in the retina. (C) Serum concentrations of anti-VEGF antibody after intravitreal injection at P14, P17, and P21 ( n = 3–6). (D) Serum VEGF concentrations after intravitreal injection of anti-VEGF antibody at P17, P21, and P28 ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. NS , not significant; **, P
Techniques Used: Injection, Mouse Assay, Staining
Figure Legend Snippet: Effects of intravitreally injected anti-VEGF antibody on BAT of neonatal mice. (A) Concentrations of VEGF in interscapular BAT at P21 and P28. The level of VEGF was normalized to total amounts of proteins in BAT ( n = 3–6). (B) Representative images of H E staining of interscapular BAT after intravitreal injection of PBS or anti-VEGF antibody show enlarged lipid droplets. Scale bar, 20 μm. (C) Quantitative analyses of vascularity of interscapular BAT based on isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). (D) Relative expression of Ucp1 and Ppargc1a in interscapular BAT ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. *, P
Techniques Used: Injection, Mouse Assay, Staining, Expressing
8) Product Images from "Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice"
Article Title: Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice
Journal: PLoS ONE
doi: 10.1371/journal.pone.0134308
Figure Legend Snippet: Long-term effects of intravitreally injected anti-VEGF antibody on BAT. (A) Quantitative analyses of the number of large lipid droplets ( > 50 μm 2 ) per field at x400 magnification ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (B) Quantitative analyses of vascularity of interscapular BAT demonstrated by isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (C) The changes in body weight from P14 to P56. Anti-VEGF, anti-VEGF antibody. NS , not significant (two-tailed, unpaired T-test).
Techniques Used: Injection, Staining, Two Tailed Test
Figure Legend Snippet: Ocular and systemic consequences of intravitreally injected anti-VEGF antibody. (A) Effects of intravitreally injected anti-VEGF antibody (1 μg/eye) on retinal neovascularization in OIR mice ( n = 6). Neovascular tufts were highlighted with yellow pseudocolor on representative images of isolectin B4-stained retina. The area of neovascular tufts was normalized to total retinal area; then, the effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). Scale bar, 200 μm. (B) Retinal VEGF concentrations at P17 with intravitreal injection of PBS or anti-VEGF antibody ( n = 3). The level of VEGF was normalized to total amounts of proteins in the retina. (C) Serum concentrations of anti-VEGF antibody after intravitreal injection at P14, P17, and P21 ( n = 3–6). (D) Serum VEGF concentrations after intravitreal injection of anti-VEGF antibody at P17, P21, and P28 ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. NS , not significant; **, P
Techniques Used: Injection, Mouse Assay, Staining
Figure Legend Snippet: Effects of intravitreally injected anti-VEGF antibody on BAT of neonatal mice. (A) Concentrations of VEGF in interscapular BAT at P21 and P28. The level of VEGF was normalized to total amounts of proteins in BAT ( n = 3–6). (B) Representative images of H E staining of interscapular BAT after intravitreal injection of PBS or anti-VEGF antibody show enlarged lipid droplets. Scale bar, 20 μm. (C) Quantitative analyses of vascularity of interscapular BAT based on isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). (D) Relative expression of Ucp1 and Ppargc1a in interscapular BAT ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. *, P
Techniques Used: Injection, Mouse Assay, Staining, Expressing
9) Product Images from "Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice"
Article Title: Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice
Journal: PLoS ONE
doi: 10.1371/journal.pone.0134308
Figure Legend Snippet: Long-term effects of intravitreally injected anti-VEGF antibody on BAT. (A) Quantitative analyses of the number of large lipid droplets ( > 50 μm 2 ) per field at x400 magnification ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (B) Quantitative analyses of vascularity of interscapular BAT demonstrated by isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (C) The changes in body weight from P14 to P56. Anti-VEGF, anti-VEGF antibody. NS , not significant (two-tailed, unpaired T-test).
Techniques Used: Injection, Staining, Two Tailed Test
Figure Legend Snippet: Effects of intravitreally injected anti-VEGF antibody on BAT of neonatal mice. (A) Concentrations of VEGF in interscapular BAT at P21 and P28. The level of VEGF was normalized to total amounts of proteins in BAT ( n = 3–6). (B) Representative images of H E staining of interscapular BAT after intravitreal injection of PBS or anti-VEGF antibody show enlarged lipid droplets. Scale bar, 20 μm. (C) Quantitative analyses of vascularity of interscapular BAT based on isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). (D) Relative expression of Ucp1 and Ppargc1a in interscapular BAT ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. *, P
Techniques Used: Injection, Mouse Assay, Staining, Expressing
10) Product Images from "Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice"
Article Title: Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice
Journal: PLoS ONE
doi: 10.1371/journal.pone.0134308
Figure Legend Snippet: Long-term effects of intravitreally injected anti-VEGF antibody on BAT. (A) Quantitative analyses of the number of large lipid droplets ( > 50 μm 2 ) per field at x400 magnification ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (B) Quantitative analyses of vascularity of interscapular BAT demonstrated by isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (C) The changes in body weight from P14 to P56. Anti-VEGF, anti-VEGF antibody. NS , not significant (two-tailed, unpaired T-test).
Techniques Used: Injection, Staining, Two Tailed Test
Figure Legend Snippet: Ocular and systemic consequences of intravitreally injected anti-VEGF antibody. (A) Effects of intravitreally injected anti-VEGF antibody (1 μg/eye) on retinal neovascularization in OIR mice ( n = 6). Neovascular tufts were highlighted with yellow pseudocolor on representative images of isolectin B4-stained retina. The area of neovascular tufts was normalized to total retinal area; then, the effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). Scale bar, 200 μm. (B) Retinal VEGF concentrations at P17 with intravitreal injection of PBS or anti-VEGF antibody ( n = 3). The level of VEGF was normalized to total amounts of proteins in the retina. (C) Serum concentrations of anti-VEGF antibody after intravitreal injection at P14, P17, and P21 ( n = 3–6). (D) Serum VEGF concentrations after intravitreal injection of anti-VEGF antibody at P17, P21, and P28 ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. NS , not significant; **, P
Techniques Used: Injection, Mouse Assay, Staining
Figure Legend Snippet: Effects of intravitreally injected anti-VEGF antibody on BAT of neonatal mice. (A) Concentrations of VEGF in interscapular BAT at P21 and P28. The level of VEGF was normalized to total amounts of proteins in BAT ( n = 3–6). (B) Representative images of H E staining of interscapular BAT after intravitreal injection of PBS or anti-VEGF antibody show enlarged lipid droplets. Scale bar, 20 μm. (C) Quantitative analyses of vascularity of interscapular BAT based on isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). (D) Relative expression of Ucp1 and Ppargc1a in interscapular BAT ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. *, P
Techniques Used: Injection, Mouse Assay, Staining, Expressing
11) Product Images from "Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice"
Article Title: Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice
Journal: PLoS ONE
doi: 10.1371/journal.pone.0134308
Figure Legend Snippet: Long-term effects of intravitreally injected anti-VEGF antibody on BAT. (A) Quantitative analyses of the number of large lipid droplets ( > 50 μm 2 ) per field at x400 magnification ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (B) Quantitative analyses of vascularity of interscapular BAT demonstrated by isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (C) The changes in body weight from P14 to P56. Anti-VEGF, anti-VEGF antibody. NS , not significant (two-tailed, unpaired T-test).
Techniques Used: Injection, Staining, Two Tailed Test
Figure Legend Snippet: Effects of intravitreally injected anti-VEGF antibody on BAT of neonatal mice. (A) Concentrations of VEGF in interscapular BAT at P21 and P28. The level of VEGF was normalized to total amounts of proteins in BAT ( n = 3–6). (B) Representative images of H E staining of interscapular BAT after intravitreal injection of PBS or anti-VEGF antibody show enlarged lipid droplets. Scale bar, 20 μm. (C) Quantitative analyses of vascularity of interscapular BAT based on isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). (D) Relative expression of Ucp1 and Ppargc1a in interscapular BAT ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. *, P
Techniques Used: Injection, Mouse Assay, Staining, Expressing
Figure Legend Snippet: Long-term effects of intravitreally injected anti-VEGF antibody on BAT. (A) Quantitative analyses of the number of large lipid droplets ( > 50 μm 2 ) per field at x400 magnification ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (B) Quantitative analyses of vascularity of interscapular BAT demonstrated by isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (C) The changes in body weight from P14 to P56. Anti-VEGF, anti-VEGF antibody. NS , not significant (two-tailed, unpaired T-test).
Techniques Used: Injection, Staining, Two Tailed Test
Figure Legend Snippet: Ocular and systemic consequences of intravitreally injected anti-VEGF antibody. (A) Effects of intravitreally injected anti-VEGF antibody (1 μg/eye) on retinal neovascularization in OIR mice ( n = 6). Neovascular tufts were highlighted with yellow pseudocolor on representative images of isolectin B4-stained retina. The area of neovascular tufts was normalized to total retinal area; then, the effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). Scale bar, 200 μm. (B) Retinal VEGF concentrations at P17 with intravitreal injection of PBS or anti-VEGF antibody ( n = 3). The level of VEGF was normalized to total amounts of proteins in the retina. (C) Serum concentrations of anti-VEGF antibody after intravitreal injection at P14, P17, and P21 ( n = 3–6). (D) Serum VEGF concentrations after intravitreal injection of anti-VEGF antibody at P17, P21, and P28 ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. NS , not significant; **, P
Techniques Used: Injection, Mouse Assay, Staining
Figure Legend Snippet: Effects of intravitreally injected anti-VEGF antibody on BAT of neonatal mice. (A) Concentrations of VEGF in interscapular BAT at P21 and P28. The level of VEGF was normalized to total amounts of proteins in BAT ( n = 3–6). (B) Representative images of H E staining of interscapular BAT after intravitreal injection of PBS or anti-VEGF antibody show enlarged lipid droplets. Scale bar, 20 μm. (C) Quantitative analyses of vascularity of interscapular BAT based on isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). (D) Relative expression of Ucp1 and Ppargc1a in interscapular BAT ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. *, P
Techniques Used: Injection, Mouse Assay, Staining, Expressing
12) Product Images from "Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice"
Article Title: Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice
Journal: PLoS ONE
doi: 10.1371/journal.pone.0134308
Figure Legend Snippet: Long-term effects of intravitreally injected anti-VEGF antibody on BAT. (A) Quantitative analyses of the number of large lipid droplets ( > 50 μm 2 ) per field at x400 magnification ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (B) Quantitative analyses of vascularity of interscapular BAT demonstrated by isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (C) The changes in body weight from P14 to P56. Anti-VEGF, anti-VEGF antibody. NS , not significant (two-tailed, unpaired T-test).
Techniques Used: Injection, Staining, Two Tailed Test
Figure Legend Snippet: Ocular and systemic consequences of intravitreally injected anti-VEGF antibody. (A) Effects of intravitreally injected anti-VEGF antibody (1 μg/eye) on retinal neovascularization in OIR mice ( n = 6). Neovascular tufts were highlighted with yellow pseudocolor on representative images of isolectin B4-stained retina. The area of neovascular tufts was normalized to total retinal area; then, the effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). Scale bar, 200 μm. (B) Retinal VEGF concentrations at P17 with intravitreal injection of PBS or anti-VEGF antibody ( n = 3). The level of VEGF was normalized to total amounts of proteins in the retina. (C) Serum concentrations of anti-VEGF antibody after intravitreal injection at P14, P17, and P21 ( n = 3–6). (D) Serum VEGF concentrations after intravitreal injection of anti-VEGF antibody at P17, P21, and P28 ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. NS , not significant; **, P
Techniques Used: Injection, Mouse Assay, Staining
Figure Legend Snippet: Effects of intravitreally injected anti-VEGF antibody on BAT of neonatal mice. (A) Concentrations of VEGF in interscapular BAT at P21 and P28. The level of VEGF was normalized to total amounts of proteins in BAT ( n = 3–6). (B) Representative images of H E staining of interscapular BAT after intravitreal injection of PBS or anti-VEGF antibody show enlarged lipid droplets. Scale bar, 20 μm. (C) Quantitative analyses of vascularity of interscapular BAT based on isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). (D) Relative expression of Ucp1 and Ppargc1a in interscapular BAT ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. *, P
Techniques Used: Injection, Mouse Assay, Staining, Expressing
13) Product Images from "Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice"
Article Title: Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice
Journal: PLoS ONE
doi: 10.1371/journal.pone.0134308
Figure Legend Snippet: Long-term effects of intravitreally injected anti-VEGF antibody on BAT. (A) Quantitative analyses of the number of large lipid droplets ( > 50 μm 2 ) per field at x400 magnification ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (B) Quantitative analyses of vascularity of interscapular BAT demonstrated by isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (C) The changes in body weight from P14 to P56. Anti-VEGF, anti-VEGF antibody. NS , not significant (two-tailed, unpaired T-test).
Techniques Used: Injection, Staining, Two Tailed Test
Figure Legend Snippet: Ocular and systemic consequences of intravitreally injected anti-VEGF antibody. (A) Effects of intravitreally injected anti-VEGF antibody (1 μg/eye) on retinal neovascularization in OIR mice ( n = 6). Neovascular tufts were highlighted with yellow pseudocolor on representative images of isolectin B4-stained retina. The area of neovascular tufts was normalized to total retinal area; then, the effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). Scale bar, 200 μm. (B) Retinal VEGF concentrations at P17 with intravitreal injection of PBS or anti-VEGF antibody ( n = 3). The level of VEGF was normalized to total amounts of proteins in the retina. (C) Serum concentrations of anti-VEGF antibody after intravitreal injection at P14, P17, and P21 ( n = 3–6). (D) Serum VEGF concentrations after intravitreal injection of anti-VEGF antibody at P17, P21, and P28 ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. NS , not significant; **, P
Techniques Used: Injection, Mouse Assay, Staining
Figure Legend Snippet: Effects of intravitreally injected anti-VEGF antibody on BAT of neonatal mice. (A) Concentrations of VEGF in interscapular BAT at P21 and P28. The level of VEGF was normalized to total amounts of proteins in BAT ( n = 3–6). (B) Representative images of H E staining of interscapular BAT after intravitreal injection of PBS or anti-VEGF antibody show enlarged lipid droplets. Scale bar, 20 μm. (C) Quantitative analyses of vascularity of interscapular BAT based on isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). (D) Relative expression of Ucp1 and Ppargc1a in interscapular BAT ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. *, P
Techniques Used: Injection, Mouse Assay, Staining, Expressing
14) Product Images from "Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice"
Article Title: Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice
Journal: PLoS ONE
doi: 10.1371/journal.pone.0134308
Figure Legend Snippet: Long-term effects of intravitreally injected anti-VEGF antibody on BAT. (A) Quantitative analyses of the number of large lipid droplets ( > 50 μm 2 ) per field at x400 magnification ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (B) Quantitative analyses of vascularity of interscapular BAT demonstrated by isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (C) The changes in body weight from P14 to P56. Anti-VEGF, anti-VEGF antibody. NS , not significant (two-tailed, unpaired T-test).
Techniques Used: Injection, Staining, Two Tailed Test
Figure Legend Snippet: Ocular and systemic consequences of intravitreally injected anti-VEGF antibody. (A) Effects of intravitreally injected anti-VEGF antibody (1 μg/eye) on retinal neovascularization in OIR mice ( n = 6). Neovascular tufts were highlighted with yellow pseudocolor on representative images of isolectin B4-stained retina. The area of neovascular tufts was normalized to total retinal area; then, the effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). Scale bar, 200 μm. (B) Retinal VEGF concentrations at P17 with intravitreal injection of PBS or anti-VEGF antibody ( n = 3). The level of VEGF was normalized to total amounts of proteins in the retina. (C) Serum concentrations of anti-VEGF antibody after intravitreal injection at P14, P17, and P21 ( n = 3–6). (D) Serum VEGF concentrations after intravitreal injection of anti-VEGF antibody at P17, P21, and P28 ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. NS , not significant; **, P
Techniques Used: Injection, Mouse Assay, Staining
Figure Legend Snippet: Effects of intravitreally injected anti-VEGF antibody on BAT of neonatal mice. (A) Concentrations of VEGF in interscapular BAT at P21 and P28. The level of VEGF was normalized to total amounts of proteins in BAT ( n = 3–6). (B) Representative images of H E staining of interscapular BAT after intravitreal injection of PBS or anti-VEGF antibody show enlarged lipid droplets. Scale bar, 20 μm. (C) Quantitative analyses of vascularity of interscapular BAT based on isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). (D) Relative expression of Ucp1 and Ppargc1a in interscapular BAT ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. *, P
Techniques Used: Injection, Mouse Assay, Staining, Expressing
15) Product Images from "Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice"
Article Title: Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice
Journal: PLoS ONE
doi: 10.1371/journal.pone.0134308
Figure Legend Snippet: Long-term effects of intravitreally injected anti-VEGF antibody on BAT. (A) Quantitative analyses of the number of large lipid droplets ( > 50 μm 2 ) per field at x400 magnification ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (B) Quantitative analyses of vascularity of interscapular BAT demonstrated by isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (C) The changes in body weight from P14 to P56. Anti-VEGF, anti-VEGF antibody. NS , not significant (two-tailed, unpaired T-test).
Techniques Used: Injection, Staining, Two Tailed Test
Figure Legend Snippet: Ocular and systemic consequences of intravitreally injected anti-VEGF antibody. (A) Effects of intravitreally injected anti-VEGF antibody (1 μg/eye) on retinal neovascularization in OIR mice ( n = 6). Neovascular tufts were highlighted with yellow pseudocolor on representative images of isolectin B4-stained retina. The area of neovascular tufts was normalized to total retinal area; then, the effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). Scale bar, 200 μm. (B) Retinal VEGF concentrations at P17 with intravitreal injection of PBS or anti-VEGF antibody ( n = 3). The level of VEGF was normalized to total amounts of proteins in the retina. (C) Serum concentrations of anti-VEGF antibody after intravitreal injection at P14, P17, and P21 ( n = 3–6). (D) Serum VEGF concentrations after intravitreal injection of anti-VEGF antibody at P17, P21, and P28 ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. NS , not significant; **, P
Techniques Used: Injection, Mouse Assay, Staining
Figure Legend Snippet: Effects of intravitreally injected anti-VEGF antibody on BAT of neonatal mice. (A) Concentrations of VEGF in interscapular BAT at P21 and P28. The level of VEGF was normalized to total amounts of proteins in BAT ( n = 3–6). (B) Representative images of H E staining of interscapular BAT after intravitreal injection of PBS or anti-VEGF antibody show enlarged lipid droplets. Scale bar, 20 μm. (C) Quantitative analyses of vascularity of interscapular BAT based on isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). (D) Relative expression of Ucp1 and Ppargc1a in interscapular BAT ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. *, P
Techniques Used: Injection, Mouse Assay, Staining, Expressing
16) Product Images from "Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice"
Article Title: Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice
Journal: PLoS ONE
doi: 10.1371/journal.pone.0134308
Figure Legend Snippet: Long-term effects of intravitreally injected anti-VEGF antibody on BAT. (A) Quantitative analyses of the number of large lipid droplets ( > 50 μm 2 ) per field at x400 magnification ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (B) Quantitative analyses of vascularity of interscapular BAT demonstrated by isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (C) The changes in body weight from P14 to P56. Anti-VEGF, anti-VEGF antibody. NS , not significant (two-tailed, unpaired T-test).
Techniques Used: Injection, Staining, Two Tailed Test
Figure Legend Snippet: Effects of intravitreally injected anti-VEGF antibody on BAT of neonatal mice. (A) Concentrations of VEGF in interscapular BAT at P21 and P28. The level of VEGF was normalized to total amounts of proteins in BAT ( n = 3–6). (B) Representative images of H E staining of interscapular BAT after intravitreal injection of PBS or anti-VEGF antibody show enlarged lipid droplets. Scale bar, 20 μm. (C) Quantitative analyses of vascularity of interscapular BAT based on isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). (D) Relative expression of Ucp1 and Ppargc1a in interscapular BAT ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. *, P
Techniques Used: Injection, Mouse Assay, Staining, Expressing
Related Articles
Recombinant:Article Title: PDGF-mediated mesenchymal transformation renders endothelial resistance to anti-VEGF treatment in glioblastoma Article Snippet: .. Cells were treated with recombinant human PDGF-AA (100 ng/ml, Peprotech, 100-13 A), PDGF-AB (100 ng/ml, Peprotech, 100-00AB), PDGF-BB (100 ng/ml, Peprotech, 100-14B), Ki8751 (3 nM, Bio-Techne, 228559-41-9), crenolanib (5 nM, ChemieTek, CP-868596), other:Article Title: Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice Article Snippet: Anti-VEGF, anti-VEGF antibody. Article Title: Pharmacological Management of Diabetic Macular Edema in Real-Life Observational Studies Article Snippet: Lastly, the results for the three different anti-VEGFs were taken together as a whole. Mouse Assay:Article Title: Molecular ablation of tumor blood vessels inhibits therapeutic effects of radiation and bevacizumab Article Snippet: Injections were performed from day 4 to 11 post tumor implantation. .. NP tumor implanted mice were treated with |
